| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YEBEH.2004.08.001 |
| P698 | PubMed publication ID | 15582830 |
| P2093 | author name string | Michael Privitera | |
| David M Ficker | |||
| P2860 | cites work | Quality-of-life and behavioral outcome measures in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards | Q34082050 |
| Seizure reduction and quality of life improvements in people with epilepsy | Q34129956 | ||
| Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone | Q34174078 | ||
| Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures | Q34195429 | ||
| Optimizing health outcomes in active epilepsy | Q34611375 | ||
| Quality of life in patients with epilepsy and impact of treatments | Q35011077 | ||
| Seizure severity in children with epilepsy: a parent-completed scale compared with clinical data | Q36850380 | ||
| Psychosocial well-being and epilepsy: an empirical study | Q39269587 | ||
| Parent- and patient-validated content for pediatric epilepsy quality-of-life assessment | Q40738885 | ||
| Patient-based assessments of quality of life in newly diagnosed epilepsy patients: validation of the NEWQOL. | Q40746669 | ||
| Quality of life for people with epilepsy. | Q40752387 | ||
| Quality of life as an outcome measure for epilepsy clinical trials | Q40877872 | ||
| Adolescents with active or inactive epilepsy or asthma: a comparison of quality of life | Q40919643 | ||
| Current issues in the management of epilepsy: the impact of frequent seizures on cost of illness, quality of life, and mortality | Q41417927 | ||
| Does carbamazepine have a narrow therapeutic plasma concentration range? | Q41714016 | ||
| Quality of life measures in epilepsy: how well can they detect change over time? | Q41735005 | ||
| Commission on Outcome Measurement in Epilepsy, 1994-1997: final report | Q41759907 | ||
| Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects | Q42251696 | ||
| Circadian carbamazepine toxicity | Q42285313 | ||
| Quality of life of people with epilepsy: a European study | Q43524508 | ||
| The short-term impact of adjunctive tiagabine on health-related quality of life | Q43718307 | ||
| Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam | Q44404649 | ||
| The relationship between seizure frequency, seizure type and quality of life: findings from three European countries | Q44733847 | ||
| Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy | Q45111234 | ||
| Measuring the impact of epilepsy: the development of a novel scale | Q47565561 | ||
| Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory | Q47762611 | ||
| Patient-oriented outcome assessment after temporal lobectomy for refractory epilepsy | Q48111468 | ||
| Gabapentin as adjunctive therapy for partial seizures | Q48740128 | ||
| Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam. | Q51076913 | ||
| Quality of life perception in patients with intractable epilepsy or pseudoseizures. | Q51097446 | ||
| Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments. | Q51114245 | ||
| The initial development of a health-related quality of life model as an outcome measure in epilepsy. | Q51140393 | ||
| Seizure frequency and the health-related quality of life of adults with epilepsy. | Q51983157 | ||
| Development of the quality of life in epilepsy inventory. | Q52012786 | ||
| Validation of a new quality of life measure for children with epilepsy. | Q52026644 | ||
| A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. | Q52047983 | ||
| Controlled release carbamazepine: cognitive side effects in patients with epilepsy. | Q52129250 | ||
| Patient-validated content of epilepsy-specific quality-of-life measurement. | Q52892849 | ||
| Risk factors for poor health-related quality of life in adolescents with epilepsy. | Q52894025 | ||
| Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. | Q53357506 | ||
| Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. | Q53359179 | ||
| Parental perception of the quality of life among children with epilepsy or diabetes with a new assessment questionnaire. | Q53494620 | ||
| A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. | Q53512831 | ||
| Self-assessment of well-being in a group of children with epilepsy. | Q53543737 | ||
| Quality of life in children with well-controlled epilepsy. | Q53622304 | ||
| The quality of life of children with chronic epilepsy and their families: preliminary findings with a new assessment measure | Q53640141 | ||
| Development of a novel scale to assess life fulfillment as part of the further refinement of a quality-of-life model for epilepsy. | Q53663971 | ||
| Development of the Quality of Life in Epilepsy Inventory for Adolescents: the QOLIE-AD-48 | Q62869098 | ||
| Seizure frequency, patient-perceived seizure severity and the psychosocial consequences of intractable epilepsy | Q67763111 | ||
| Epilepsy and the quality of everyday life. Findings from a study of people with well-controlled epilepsy | Q68108985 | ||
| Differences in side effects between a conventional carbamazepine preparation and a slow-release preparation of carbamazepine | Q68534669 | ||
| Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study | Q68601068 | ||
| Pharmacokinetic comparison of two carbamazepine slow-release formulations | Q68628574 | ||
| Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects | Q70580473 | ||
| Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects | Q71264853 | ||
| The associations of psychopathology in epilepsy: a community study | Q71716131 | ||
| Childhood epilepsy and asthma: comparison of quality of life | Q72048778 | ||
| Seizure severity and the quality of life | Q72852953 | ||
| The impact of epilepsy from the patient's perspective I. Descriptions and subjective perceptions | Q74106979 | ||
| Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures | Q77690646 | ||
| Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin | Q77936113 | ||
| Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR) | Q93921189 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 841-846 | |
| P577 | publication date | 2004-12-01 | |
| P1433 | published in | Epilepsy Behavior | Q15746410 |
| P1476 | title | Assessment of adverse events and quality of life in epilepsy: design of a new community-based trial | |
| P478 | volume | 5 |
| Q60948255 | Adverse Events of Antiepileptic Drugs Using Indonesian Version of Liverpool Adverse Events Profile |
| Q90467903 | Improvement of quality of life in adolescents with epilepsy after an empowerment and sailing experience |
| Q47772365 | Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures. |
| Q37313439 | Minimizing AED adverse effects: improving quality of life in the interictal state in epilepsy care |
| Q34086531 | Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study. |
| Q36270316 | Optimizing antiepileptic drug therapy in the elderly |
| Q45022494 | Predictors of health-related and global quality of life among young adults with difficult-to-treat epilepsy and mild intellectual disability |
| Q34158012 | The Art of Managing Conversions between Antiepileptic Drugs: Maximizing Patient Tolerability and Quality of Life |
| Q40671157 | The effect of self-management training on health-related quality of life in patients with epilepsy |
Search more.